Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abemaciclib

FDA-approved product (tablet, oral), marketed as Verzenio.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Abemaciclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abemaciclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abemaciclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Abemaciclib (LY2835219) in Healthy Participants

    NCT07818967 · start 2026-09

    Registered record
    Registry ID
    NCT07818967
    Conditions
    Healthy Volunteers
    Interventions
    Abemaciclib Tablet (Test Formulation); Abemaciclib Tablet (Reference Formulation); Abemaciclib Oral Granules (Test Formulation)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2026-11
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAbemaciclib Tablet (Test Formulation); Abemaciclib Tablet (Reference Formulation); Abemaciclib Oral Granules (Test Formulation)
    PhasePhase 1
    Registry statusNot yet recruiting

  • Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

    NCT07706933 · start 2026-08-01

    Registered record
    Registry ID
    NCT07706933
    Conditions
    Breast Cancer
    Interventions
    Dalpiciclib; Abemaciclib/Ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2033-06-30
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDalpiciclib; Abemaciclib/Ribociclib
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

    NCT07767474 · start 2026-08-01

    Registered record
    Registry ID
    NCT07767474
    Conditions
    Advanced Solid Tumors
    Interventions
    ATX-898; ATX-898; ATX-898; ATX-898; ATX-898; ATX-898, fulvestrant, ribociclib; ATX-898, fulvestrant, ribociclib; ATX-898, fulvestrant, ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-01-31
    Enrolment
    343

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionATX-898; ATX-898; ATX-898; ATX-898 +4 more
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

    NCT07191717 · start 2026-05-18

    Registered record
    Registry ID
    NCT07191717
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma; Localized Estrogen Receptor-Positive Breast Carcinoma; Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
    Interventions
    Abemaciclib; Biospecimen Collection; Imlunestrant; Questionnaire Administration; Radiologic Imaging Procedure
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-18
    Completion
    2031-04-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma +2 more
    InterventionAbemaciclib; Biospecimen Collection; Imlunestrant; Questionnaire Administration +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

    NCT07475923 · start 2026-04-09

    Registered record
    Registry ID
    NCT07475923
    Conditions
    Molecular Surveillance; Breast Cancer; ctDNA; MRD; Observational Study
    Interventions
    Blood draw for the laboratory assessment; Neoadjuvant treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2026-04-09
    Completion
    2026-04-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMolecular Surveillance; Breast Cancer; ctDNA; MRD +1 more
    InterventionBlood draw for the laboratory assessment; Neoadjuvant treatment
    PhaseNot recorded
    Registry statusWithdrawn

  • Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

    NCT07292207 · start 2026-01-10

    Registered record
    Registry ID
    NCT07292207
    Conditions
    ctDNA Monitoring; Breast Cancer
    Interventions
    Abemaciclib 150 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-01-10
    Completion
    2031-08-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionctDNA Monitoring; Breast Cancer
    InterventionAbemaciclib 150 MG Oral Tablet
    PhasePhase 2
    Registry statusNot yet recruiting

  • Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    NCT07037199 · start 2025-08-18

    Registered record
    Registry ID
    NCT07037199
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-18
    Completion
    2030-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab rezetecan + CDK4/6 inhibitors + endocrine therapy
    PhasePhase 2
    Registry statusRecruiting

  • A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    NCT07114601 · start 2025-08-06

    Registered record
    Registry ID
    NCT07114601
    Conditions
    Breast Neoplasms; Colorectal Neoplasms; Prostate Neoplasm; Endometrial Neoplasms; Neoplasm Metastasis; Stomach Neoplasms; Esophageal Neoplasms
    Interventions
    LY4257496; Standard of Care Anticancer Therapies; LY4257529
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-08-06
    Completion
    2035-04
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Colorectal Neoplasms; Prostate Neoplasm; Endometrial Neoplasms +3 more
    InterventionLY4257496; Standard of Care Anticancer Therapies; LY4257529
    PhasePhase 1
    Registry statusRecruiting

  • Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

    NCT06486883 · start 2025-06-30

    Registered record
    Registry ID
    NCT06486883
    Conditions
    Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    Interventions
    Trastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-30
    Completion
    2028-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma
    InterventionTrastuzumab deruxtecan (T-DXd, DS-8201a); CDK4/6i plus ET
    PhasePhase 2
    Registry statusRecruiting

  • ALPINE: Maintenance Letrozole/Abemaciclib

    NCT06366347 · start 2024-09-25

    Registered record
    Registry ID
    NCT06366347
    Conditions
    Endometrial Cancer; Recurrent Endometrial Cancer; TP53
    Interventions
    Abemaciclib; Letrozole; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-25
    Completion
    2029-03-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer; Recurrent Endometrial Cancer; TP53
    InterventionAbemaciclib; Letrozole; Pembrolizumab
    PhasePhase 2
    Registry statusRecruiting

  • A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

    NCT06495164 · start 2024-06-24

    Registered record
    Registry ID
    NCT06495164
    Conditions
    Breast Cancer; Malignant Neoplasm of Breast
    Interventions
    Palbociclib; Aromatase inhibitor; Ribociclib; Abemaciclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-06-24
    Completion
    2026-12-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Malignant Neoplasm of Breast
    InterventionPalbociclib; Aromatase inhibitor; Ribociclib; Abemaciclib
    PhaseNot recorded
    Registry statusActive not recruiting

  • DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

    NCT06388122 · start 2024-04-30

    Registered record
    Registry ID
    NCT06388122
    Conditions
    HER2-negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Metastatic Breast Cancer; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma
    Interventions
    Biospecimen Collection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-04-30
    Completion
    2031-06-15
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Metastatic Breast Cancer; Anatomic Stage II Breast Cancer AJCC v8 +5 more
    InterventionBiospecimen Collection
    PhaseNot recorded
    Registry statusRecruiting

  • Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

    NCT06169371 · start 2023-12-28

    Registered record
    Registry ID
    NCT06169371
    Conditions
    Breast Cancer
    Interventions
    Abemaciclib; Abemaciclib; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-12-28
    Completion
    2030-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAbemaciclib; Abemaciclib; Abemaciclib
    PhasePhase 4
    Registry statusRecruiting

  • A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

    NCT06188520 · start 2023-12-05

    Registered record
    Registry ID
    NCT06188520
    Conditions
    ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)
    Interventions
    AZD8421; Camizestrant; Ribociclib; Palbociclib; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-12-05
    Completion
    2027-08-04
    Enrolment
    564

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)
    InterventionAZD8421; Camizestrant; Ribociclib; Palbociclib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • ETHAN - ET for Male BC

    NCT05501704 · start 2023-10-11

    Registered record
    Registry ID
    NCT05501704
    Conditions
    Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma
    Interventions
    Tamoxifen; Anastrozole; Degarelix; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-10-11
    Completion
    2036-04-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma
    InterventionTamoxifen; Anastrozole; Degarelix; Abemaciclib
    PhasePhase 2
    Registry statusRecruiting